Blue Toad™ is different – we understand that gut health is key to a healthy 5-HT2A serotonin response & building upon that science, we use patented & clinically validated ingredients, adaptogenic botanicals under the guidance of Ayurvedic principles, fungi & nootropics giving consumers effective need-state support (Pain, Sleep, PMS, Anxiety, Immunity, Gut Biome, Migraines, Joint Pain, Hormones, etc.).
RESEARCH & DEVELOPMENT PRINCIPLES & OBJECTIVES
Our core focus is to develop novel ingredients & protocols that have broad impact on specific need-states and the biological homeostasis of our consumers, while also modulating 5-HT2A, CB1/ CB2/ GPR55/ TRPV1 (and other) receptors & their binding molecules. These improvements include balancing of the glutamatergic & ECS systems, efficacy of receptors/agonists, speed to action, long term potentiation (LTP), bioavailability, etc. Key areas of R&D are effective delivery formats, co-extraction, fermentation & metabolites, use of botanicals for a full entourage effect, effective need-state stacks, specific myco strains & their whole-plant constituents for maximum Therapeutic Outcomes for Consumer Indications.
Our tools (plants & fungi) are based in both current science as well as the principles of Mesoamerican, TCM & Ayurvedic Medicine, they include: organic botanicals, Amanita Muscaria, Salvia Divinorum, Banisteriopsis Caapi, Morning Glory Seeds (Ergoline Alkaloid, /D-lysergic acid amide (LSA), Psilocybin, Mimosa Tenuiflora, Hemp, additional alkaloids (baeocystin, norbaeocystin, ß-carbolines, aeruginascin, norpsilocin and psilocin), neurotransmitter Anandamide/ AEA, fatty acids, terpenes, enzymes, theobromine, FAAH inhibitors, GABA, glutamate, and many more. Our research partner, ISU’s (Idaho State University) Psychopharmacology Lab, is capable of handling Schedule 1 Drugs (Psilocybin, MDMA, 5 MEo-DMT) & is a well equipped state-of-the-art Zebrafish Preclinical Drug Discovery Lab. Zebrafish are valuable biomedical models & our ISU lab will be able to run literally hundreds of protocols per week to ensure speed-to-outcome. The Toad sees a huge market opportunity in “post therapeutic” clinical microdosing products sold through targeted channels.